Abstract: An unprecedented set of structurally diverse sulfonimidamides( 47 compounds) has been prepared by various N-functionalization reactions of tertiary =NH sulfonimidamide 2aa.T hese N-functionalization reactions of model compound 2aa include arylation, alkylation, trifluoromethylation, cyanation, sulfonylation, alkoxycarbonylation (carbamate formation) and aminocarbonylation (urea formation). Small molecule X-ray analyses of selected N-functionalized productsa re reported. To gain furtheri nsight into the properties of sulfonimidamidesr elevant to medicinal chemistry,avariety of structurally diverser eaction products were tested in selected in vitro assays. The described N-functionalization reactions provide as hort and efficient approach to structurally diverses ulfonimidamidesw hich have been the subject of recent, growingi nterest in the life sciences.
Introduction
The sulfonamide group 1 (Figure 1 ) is an important pharmacophore found in about2 00 drugs currently on the market.
[1] In contrast, sulfonimidamides 2,t he mono-aza analogues of sulfonamides 1,h ave received little interest until recently,d espite being first synthesized as early as 1962. [2] The infrequent take-up of the sulfonimidamide group asapharmacophore is surprising since it seems to offer very interesting properties, including high stability, favorable physicochemical properties, multiple hydrogen-bond acceptor/donor functionalities and structuraldiversity. [3] Possible reasons for the neglected use of the sulfonimidamide group are the lack of commercial availability and limited synthetic methods for its preparation, [4] as well as an incomplete understanding of its medicinal chemistry properties. However,a sr ecently pointed out by Arvidssona nd co-workers, the sulfonimidamide group is currently gaining popularity as a novelp harmacophore in thel ifes ciences. [3] Examplesi nclude thes ulfonimidamide analogues 5 and 6 of thec linicals ulfonamide-containing anticancer agenttasisulam [5] andn on-steroidal anti-inflammatory drug celecoxib, [6] respectively,aswellasanincreasing number of sulfonimidamides claimedi npatentapplications, fori nstancet he sodium channeli nhibitor 7 (Figure2). [7] However, to the best of our knowledge,as ulfonimidamide candidate for clinicaltesting has yet to be disclosed.
This increasing interesti nt he life sciences is supported by the very recent advent of new and safe synthetic methods for the preparation of sulfonimidamides 2.L atest developments include the copper-catalyzed conversion of sulfoximines 4 into sulfonimidamides 2, [8] the preparationo ft rifluoromethylated sulfonimidamides [9] and the one-pot de novo synthesis of sulfonimidamides relying on the stable reagent N-sulfinyltritylamine. [6] Triggered by our experience that the use of uncommon functional groups, such as sulfoximines 4, [10] can be crucial for overcoming hurdles in lead optimization, [11] we also became interested in sulfonimidamides 2 as an eglected but potentially versatile pharmacophore for drug discovery. Due to the limited synthetic methodology available, we developed an ew,p ractical one-pot synthesis of tertiary =NH sulfonimidamides 2a by transfer of electrophilic NH to sulfinamides 3 (Scheme 1). [12] The reaction is mediated by commercially available (diacetoxyiodo)benzene and ammonium carbamate in methanola tr oom temperature and tolerates aw ide range of functional groups. Originally,t hese reactionc onditions had been newly reported by Bull, Luisi and co-workers [13] for the conversiono fs ulfoxides into sulfoximines 4.M oreover,w ei nvestigated av ariety of in vitro properties, relevant to medicinal chemistry,o f=NH sulfonimidamide 2aa in comparison to its matched sulfonamide analogue 1aa and did not identify any intrinsic flaw of the =NH sulfonimidamide group with respect to its application in the life sciences. [12] However,i nc ontrastt os ulfonamides 1, =NH sulfonimidamides 2a offer the possibility of exploration of novel chemical space via the introduction of substituents at the =NH position. Functionalization of this =NH position would also offer an additional handle to modulate the overall properties of the resulting molecules, for example with respect to conformational behavior,lipophilicity andp hysicochemical properties.
Therefore, we set course to investigate the N-functionalization of tertiary =NH sulfonimidamides 2a.T ot est the desired transformations, we selected =NH sulfonimidamide 2aa as a model compound, which hadb een prepared from the corresponding sulfinamide 3 on ag ram scale by the one-pot NHtransfer method (Scheme 1). [12] With respect to the reactivity of the =NH position, we expected ac ertains imilarity of sulfonimidamides and sulfoximines. Therefore, we elected to probe reaction conditions for the desired N-functionalizations of =NH sulfonimidamides that we had already successfully employed for the analogous reactions of =NH sulfoximines, even on complex, drug-like molecules. [14] Results and Discussion
The palladium-catalyzed coupling of =NH sulfoximines with aryl bromides was first described in 1998 by Bolm andH ildebrand who used catalytic amountso fP d(OAc) 2 and ac helating bisphosphine (e.g.,B INAP)i nt he presence of Cs 2 CO 3 as a base. [15] In the meantime, av ariety of modified reactionc onditions and reagents have been described by both academic and industrial groups. [16] In our drug discovery efforts, we had relied on the catalyst system Pd 2 (dba) 3 /BINAP [14e, i] or Pd 2 (dba) 3 / Xantphos [17] in toluene in the presence of Cs 2 CO 3 for this type of reaction. However,i na no ngoing lead optimization approach,w er ecently switched to the combination of Pd(OAc) 2 and Xantphos as ac atalysts ince the use of Pd 2 (dba) 3 resulted in purification issues. [18] In contrasttothe broad variety of N-arylationm ethods availablef or =NH sulfoximines, as far as we are aware there is only one report of the analogous palladiumcatalyzed coupling reaction of =NH sulfonimidamides. Thus, Arvidssona nd co-workers used RuPhos and 2nd generation RuPhosp recatalyst in THF in the presence of NaOtBu under microwavec onditions;n evertheless, only four structurally simplep roducts, having no substituents at the aryl group, were described.
[19] The same research group also successfully investigated the copper-catalyzedc oupling of =NH sulfonimidamides with boronic acids.
[20] However,w ew ere mainly interested in the N-arylation of =NH sulfonimidamides using aryl halides, due to better availability and reduced costs. Hence, conditions that we had successfully applied for the analogous functionalization of =NH sulfoximines were tested. As am odel reaction,t ertiary =NH sulfonimidamide 2aa (100 mg, 0.45 mmol, 1.1 equiv) was treated with bromobenzene (8a, 1equiv) in the presence of catalytic amounts of Pd(OAc) 2 (5 mol %) and Xantphos (10 mol %), along with Cs 2 CO 3 (1.5 equiv), in toluene at 100 8Co vernight. To our delight, the desired coupling product 2ba was isolated in 86 %y ield after columnc hromatography (Table 1) . Given the clean reaction and very good yield, we then elected to explore the substrate scope of this new process. Av ariety of substituted aryl bromides 8b-l were subjected to the standard reactionc onditions. Gratifyingly,t he desired products 2bb-2bl were afforded in all cases, the majority in good to excellent yields Figure 2 . Structures of the sulfonimidamide analogues 5 and 6 of the clinical sulfonamide-containing anticancer agent tasisulam [5] and non-steroidal anti-inflammatory drugc elecoxib, [6] as well as of the sodium channel inhibitor 7 [7] disclosed in ar ecent patent application.
Scheme1.Synthesis of N-functionalized tertiarysulfonimidamides by various methods using =NH sulfonimidamide 2aa as amodel compound.
( Table 1 ). The exception wast he reactiono f2 -bromo-1,3,5-trimethylbenzene (8h)w hichg ave the coupling product 2bh in very low yield (3 %). This is probably due to steric hindrance resulting from the two methyl groupsa tt he positions ortho to the bromine, since the monosubstitutedb romotoluenes 8e-g all resulted in very good yields. Coupling product 2bk was successfully recrystallizeda nd the structure confirmed by X-ray analysis( Figure 3) [for additional X-ray analyses( compounds 2bg, 2bj and 2bm), see the Supporting Information]. The reactiono fv arioush eteroaryl bromides 8m-q also gave the desired heteroaromatic products 2bm-2bq in good yields.
Another important option for the N-functionalization of =NH sulfoximines and =NH sulfonimidamides is the corresponding N-alkylation reaction. It is noteworthy that all recent sulfoximine clinical candidates, the kinase inhibitors roniciclib (BAY 1000394), [11a, 21] atuveciclib (BAY1 143572), [22] AZD 6738 (Figure 4 ) [23] and BAY1 251152 (Figure 4 ), [24] contain an unsubstituted =NH group. However,s ince for instance lowC aco2 permeability and high efflux can be an issue with =NH sulfoximines, [10e] N-alkylation may be am eanso fi mproving the permeability properties.
[10d] Moreover,N -alkylation is an interesting optionf or drug design to exploren ovel chemical space. Satzingera nd Stoss, who pioneered the use of the sulfoximine groupi nd rug discovery, were originally attractedt ot hisf unctional groupbythispossibility of introducingsubstituentsatt he =NH position.T heir lead optimization effortsl ed to thei dentification of thef irst sulfoximinec linicalc andidate suloxifen, which is an N-alkylated diphenyl sulfoximine (Figure 4 ). [10c, 25] Direct N-alkylation of =NH sulfoximines is not at rivial task since the nucleophilicity of the nitrogen is dramatically reduced due to stericand electronic effects of the adjacent tetracoordinated sulfur. [26] N-Methylation of =NH sulfoximinesh as usually been achieved under Eschweiler-Clarke conditions or by the use of as trong methyl-transfer agent. [27] Introduction of more complex alkyl groups, however,r emained difficultu ntil Bolm and co-workers introduced an ew methode mploying alkyl bromides and KOH as ab ase in DMSO at room temperature. [28] So far,t here have been scant reports of the corresponding direct N-alkylation of =NH sulfonimidamides, the first from Johnson and Lavergne. [26, 29] They discovered that while Eschweiler-Clarke conditions resulted in degradation of the =NH sulfonimidamide startingm aterials, the use of primary alkyl bromides in combination with KH and the phase-transfer catalyst Bu 4 NBr in 1,2-dimethoxyethane gave the desired N-alkylation products in good to excellent yields. In contrast, secondary bromides did not provide the N-alkylated products under these conditions.
Along the lines of our concept to apply successful reaction conditions from our experience with =NH sulfoximines in drug discoveryt o=NH sulfonimidamides, we investigated the N-alkylationo fm odel compound 2aa using alkyl bromides in the presenceo fK OH in DMSO.I nt he first reaction, tertiary =NH sulfonimidamide 2aa (100 mg, 0.45 mmol,1equiv) wast reated with bromoethane (9a,1 .5 equiv)i nD MSO in the presence of KOH (2 equiv) for 4hours at room temperature, to give the desired N-ethyld erivative 2ca in 99 %i solated yield ( Table 2) . www.chemeurj.org
After this initial success,t he substrate scope of this new process was explored using alkyl bromides 9b-l.I nc ontrast to Johnson and Lavergne's method, [26] reactiono ft he secondary alkyl bromide 2-bromopropane (9b)a lso gave the desired product 2cb,a lbeit in as ignificantly reduced yield of 38 %. Reaction of 2aa with av ariety of more complex alkyl bromides 9c-k gave the corresponding N-alkylation products, usually in good to moderate yields. Similar to the reported results of the N-alkylation of sulfoximines, [28] the use of N-(2-bromoethyl)-N,N-diethylamine (9l)r esulted in al ow 13 %y ield. However, the correspondingp roduct 2cl can be considered as ap artially saturated sulfonimidamide analogueo ft he potent spasmolytic and antiasthmatic agents uloxifen (Figure 4 ). Since methyl bromide is ag as, we employed methyli odide for the desired Nmethylation reaction of 2aa to isolate the methylated product 2cm in 59 %y ield. Benzyl bromide (9n)r eacted with 2aa in as imilar yield of 57 %( 2cn), andp roduct 2co was isolated from the reaction with heterocyclic 3-(bromomethyl)-5-methylisoxazole (9o)i ng ood yield. Moreover,t he reactions of allyl bromide (9p)and propargylic bromides 9q,r also gave the corresponding products 2cp-2cr in good yields.
Bolm and co-workersr ecently achieved the first N-trifluoromethylation of =NH sulfoximines. [30] This radical process relies on the use of TMSCF 3 as at rifluoromethylating agent andc atalytic amounts of Ag 2 CO 3 and 1,10-phenanthroline under an oxygen atmosphere. The introduction of trifluoromethyl substituentsi sn ow aw ell-accepted strategy in medicinal chemistry,sinceitc an significantly alter the properties of the resulting compounds, for example with respect to lipophilicity,m etabolic stabilitya nd conformational behavior.
[31] Since N-trifluoromethylationo f=NH sulfonimidamides has not been reported, we were intrigued to apply the above conditions to model compound 2aa.T oo ur delight, the desired product 2cs was formed and could be isolated in 44 %y ield (Scheme2)w ithout furtheroptimization.
N-Cyanationo f=NH sulfoximinesi sa nother interesting designo ption in the life sciences. The resulting =NÀCN sulfoximine group is, for instance, present in the only marketed sulfoximines of ar,t he insecticide sulfoxaflor (Figure 4) . [32] In the past, we and others have relied on the reaction of =NH sulfoximines with cyanogen bromide to prepare =NÀCN sulfoximines. [33] There is also one reportb yG namm and co-workers of the successful application of this methodf or the preparation of an =NÀCN sulfonimidamide derivative. [34] However, given the high toxicityo ft he required cyanogen bromide, a new,e nvironmentally benign procedure caughto ur attention. Thus, Cheng and co-workersr ecently reported the direct copper-catalyzed N-cyanationo f=NH sulfoximines using AIBN as as afe cyanide source. [35] Given the successful N-trifluoromethylationo f=NH sulfonimidamide 2aa under radical conditions (Scheme 2), we elected to apply the new radicalN -cyanation process of sulfoximines to =NH sulfonimidamide model compound 2aa and at once isolatedt he corresponding product 2da in 43 %yield (Scheme 3).
N-Sulfonylated sulfoximines can be prepared by the reaction of =NH sulfoximinesw ith sulfonyl chlorides. [36] There are various reported N-(sulfonyl)sulfonimidamides, [37] but none ob- tained by the direct reaction of =NH sulfonimidamides with sulfonyl chlorides. Nevertheless, the reactiono fm odel compound 2aa with sulfonyl chlorides 10 a,b in pyridine at room temperature gave the desired coupling products in good yields (Table 3) .
The carbamate group is ak ey structural motif in many approvedd rugs. [38] Sulfoximines and sulfonimidamides also offer the opportunity to form carbamate-type products by employing the =NH position. The first N-(sulfoxylidene)carbamatew as described in 1970 [25a] and products of this type are usually synthesized by the reaction of =NH sulfoximinesw ith chloroformates. [39] Carbamatesb ased on sulfonimidamidesw ere already describedi n1 963 [40] but, to the best of our knowledge, there is only one literature example of ad irect coupling of an =NH sulfonimidamide with ac hloroformate.
[39b] To gain further insight into this straightforward method, =NH sulfonimidamide model compound 2aa was reactedw ith chloroformates 11 a,b in pyridine to give the coupling products in good yields (Table 4) .
Like the carbamate group,t he urea moiety is av ery important pharmacophore in the life sciences.
[41] The formation of N-(sulfoxylidene)urea derivatives via reaction of the =NH group of sulfoximines with isocyanates was described as early as 1965. [42] We have also successfully applied this reaction in av ariety of lead optimization programs.
[43] In comparison, very few sulfonimidamide-based ureas have been described as yet.
[44] As far as we are aware,n one of these products was obtained by the direct reaction of an =NH sulfonimidamide with an isocyanate. However,t he reaction of =NH sulfonimidamide model compound 2aa with isocyanates 12 a-f in dichloromethane at room temperature gave the desired couplingp roducts in good yields (Table 5) .
In ar ecent, preliminarya ssessment of the medicinal chemistry properties of sulfonimidamides, the behavior of =NH sulfonimidamide 2aa was compared to the matched sulfonamide analogue 1aa in selected in vitro assays. [12, 45] The hydrolytic stability of both compounds at different pH values was investigated, alongw ith the metabolic stabilityi nl iver microsomes (human, rat and mouse) and also rat hepatocytes in vitro. Furthermore, the Caco2 permeability and logD values were determined. In vitro, model compound 2aa didn ot reveal any intrinsic flaw of the sulfonimidamide group with respect to its application in the life sciences.
To gain furtherk nowledge of the properties of the neglected sulfonimidamide group, selected N-functionalized sulfonimidamides were evaluated in the same in vitro panel (Table 6 containss elected examples;s ee the Supporting Information for additional examples). Similar to =NH sulfonimidamide 2aa, the tested N-functionalized sulfonimidamidesr evealed very high hydrolytic stabilities after 24 hours with stirring at pH 1, 7 and 10. The only exception was N-trifluoromethylated sulfonimidamide 2cs that revealed signs of hydrolysis at pH 1a nd 10.
As expected, introduction of as ubstituent at the =NH position significantly influences the lipophilicity of the resulting compounds. Depending on the nature of the substituent, logD values in the range of 1.9( 2cl)u pt o4 .3 (2bc)w ere recorded. Introduction of am ethyl group at the =NH position, for instance,r esulted in an increased logD value from 1.9 (2aa)t o 2.4 (2cm), whereas the introductiono fatrifluoromethyl group raised the logD value to 3.7 (2cs).
All compoundsw ere tested in aC aco2 screeninga ssay and revealed high permeability coefficients (P app A-B)a nd no evidence of drug efflux. This behavior can be attributed to the In vitro pharmacokinetics tudies in liver microsomes of human, rat and mouse origin, and rat hepatocytes, with selected N-functionalized sulfonimidamidesr evealed ac lear species dependence of the predicted metabolic stabilities, given as the maximum oral bioavailability F max [46] (Table 6a nd SupportingI nformation). From the studies with rat hepatocytes, low metabolic stabilities (F max < 30 %) were observed fora ll tested sulfonimidamides as well as sulfonamide 1aa.S imilar instabilities were also observed with rat liver microsomes, which is well in line with the unrestricted membrane permeability observed in Caco2 cells and hints at am ajor involvement of Phase Im etabolism for these compounds in rats. Based on liver microsomes from humans,h owever,t he metabolic stabilities cover the whole range, from high (F max > 70 %; e.g., 2cl, 2ea)t ol ow (F max < 30 %; e.g., 2bc). This range of metabolic stabilities in human liver microsomesc orrelates nicely with the corresponding logD values of the test compounds (see the Supporting Information), which is in line with the general trend for many chemical series in the life sciences. [47] However, it is noteworthy that the main sites of metabolism and the involved metabolic enzymes were not determined in these in vitro studies.
Conclusions
Althougho verlookedi nt he life sciences for al ong time, the sulfonimidamide functional group has recently been the subject of ag rowing interesta saversatile pharmacophore. Based on the premise that the =NH position of tertiary sulfonimidamides shoulds how as imilarr eactivity as the =NH position of sulfoximines, we have successfully applied variousr eported re- Efflux ratio [c] logD pH 7.5 [d] 100 (1) 100 (7) 100 (10) 69 ( 100 (1) 100 (7) 100 (10) 97 ( Efflux ratio [c] logD pH 7.5 [d] 100 (1) 100 (7) 100 (10) 8 [a] Hydrolytic stability measured as recovery of test compounda fter 24 hours with stirringa tp H1 (HCl buffer), pH 7( phosphate-buffered saline) and pH 10 (sodium borate buffer). [48] [b] Predicted hepatic metabolic first pass given as the maximum oralb ioavailability F max based on a metabolic stability assay using( i) pooled humanl iver microsomes (hLMs), (ii)pooled rat liver microsomes (rLMs), (iii)pooled mouse liver microsomes (mLMs)a nd (iv) freshly harvestedrath epatocytes (rHep). [49] [c] P app A-B (apicalt ob asolateral) and efflux ratio (ER) data were generated in ab idirectionally performed Caco2 permeability assay in a2 4-well format;E R was calculated as P app B-A/P app A-B. [49] [d] Determined by reversed-phase HPLC. [50] Chem.E ur.J.2018, 24,9295 -9304 www.chemeurj.org 2018 The Authors. Published by Wiley-VCH Verlag GmbH &Co. KGaA, Weinheim action conditions for the N-functionalization of sulfoximines to the tertiary =NH sulfonimidamide model compound 2aa. Using this methodology,w eh aves ynthesized anu nprecedented set of structurallyd iverse sulfonimidamides( 47 compounds). The described N-functionalizationr eactions include arylation,a lkylation, trifluoromethylation, cyanation, sulfonylation, alkoxycarbonylation (carbamate formation)a nd aminocarbonylation (urea formation). Generally,o nly isolated examples of these transformationsh ave been reported previously,a nd we have utilized many of the describedr eactions for the first time for the N-functionalization of =NH sulfonimidamides. In vitro studies of selected, structurally diverseN -functionalized sulfonimidamides from our set of compounds have not revealed any intrinsic flawo ft he sulfonimidamide group with respect to its applicationa saversatile pharmacophore in drug discovery. The combination of our recently reported one-pot synthesis of tertiary =NH sulfonimidamides by NH transfer to simple sulfinamidesa nd the subsequent N-functionalization of the newly formed =NH positione mploying the now-outlined set of reactions offers rapid access to highly complex and structurally diversem olecules, addressing novel chemical space with properties suitable for applicationi nt he life sciences.
Experimental Section N-Arylation of sulfonimidamide 2aa: General procedure A
In ad ry MW vial flushed with Ar,s ulfonimidamide 2aa (100 mg, 0.45 mmol, 1.1 equiv) and an aryl bromide (0.40 mmol, 1.0 equiv) were dissolved in toluene (6.8 mL). The mixture was then degassed for 10 min and Pd(OAc) 2 (4.5 mg, 0.02 mmol, 5mol %), Xantphos (23 mg, 0.04 mmol, 10 mol %) and Cs 2 CO 3 (200 mg, 0.60 mmol, 1.5 equiv) were added at RT.T he reaction mixture was heated to 100 8Ca nd stirred overnight. Once the starting material had been consumed (monitored by TLC), the mixture was cooled, diluted with methyl tert-butyl ether,f iltered through ap ad of Celite under reduced pressure and washed with methyl tert-butyl ether.S olvent was removed under reduced pressure and the crude product was purified by flash column chromatography. N-Alkylation of sulfonimidamide 2aa: General procedure B [28] In ad ry MW vial flushed with Ar,s ulfonimidamide 2aa (100 mg, 0.45 mmol, 1.0 equiv) and KOH (50 mg, 0.89 mmol, 2.0 equiv) were stirred in DMSO (0.7 mL) at RT for 15 min. Then, an alkyl bromide/ iodide (0.67 mmol, 1.5 equiv) was added and the mixture was stirred at RT for 4-16 h. Once the starting material had been consumed (monitored by TLC), H 2 Ow as added and the aqueous layer was extracted with DCM (3 10 mL). The combined organic phases were filtered through water-repellent filter paper.S olvent was removed under reduced pressure and the crude product was purified by flash column chromatography or preparative HPLC.
1-(N-Ethyl-S-phenylsulfonimidoyl)piperidine (2 ca)
Prepared according to general procedure B, from bromoethane; crude purified by flash column chromatography (KP-Sil, 0-50 % EtOAc in hexane) to give 2ca as ac olorless oil (111 mg, 99 N-Trifluoromethylation of sulfonimidamide 2aa [30] 1 N-Cyanation of sulfonimidamide 2aa [35] N-[Oxo(phenyl)(piperidin-1-yl)-l
-sulfanylidene]cyanamide (2 da)
In aM Wv ial charged with sulfonimidamide 2aa (100 mg, 0.45 mmol, 1.0 equiv), AIBN (108 mg, 0.66 mmol, 1.5 equiv), CuI (16 mg, 0.09 mmol, 0.2 equiv), K 2 CO 3 (122 mg, 0.88 mmol, 2.0 equiv) and MeCN (6.7 mL) were added. Then, aballoon charged with O 2 was attached to the MW vial and the solution was degassed for 10 min. The mixture was stirred and heated in an oil bath at 75 8Cf or 16 h. Then, the solution was cooled, filtered and the solids washed with MeCN. The liquid phase was collected, solvent removed in vacuo and the crude product purified by flash column chromatography (KP-Sil, 0-100 %E tOAc in PE) to give 2da as ab rown oil (47 mg, 43 N-Sulfonylation of sulfonimidamide 2aa: General procedure C Sulfonimidamide 2aa (100 mg, 0.45 mmol, 1.0 equiv) was dissolved in pyridine (3.0 mL) under Ar atmosphere;t hen, the appropriate sulfonyl chloride (0.71 mmol, 1.6 equiv) was added. The reaction mixture was stirred at RT overnight;t hen, the reaction was quenched with aqueous NaHCO 3 and diluted with EtOAc (3 mL). The mixture was transferred to as eparating funnel, the aqueous layer was extracted with EtOAc (3 10 mL), and the combined organic phases were washed with brine (3 10 mL), then filtered through water-repellent filter paper.S olvent was removed in vacuo and the crude product purified (when needed).
N-[Oxo(phenyl)(piperidin-1-yl)-l N-Alkoxycarbonylation of sulfonimidamide 2aa( carbamate formation): General procedure D [51] To as olution of sulfonimidamide 2aa (100 mg, 0.45 mmol, 1.0 equiv) and pyridine (54 mL, 0.67 mmol, 1.5 equiv) in THF (0.9 mL) under Ar atmosphere at 0 8C, the corresponding chloroformate (0.67 mmol, 1.5 equiv) was added. As soon as the chloroformate was in solution, aw hite precipitate formed. The temperature was allowed to rise to RT and the mixture was stirred overnight. The reaction was quenched with H 2 Oa nd diluted with Et 2 O (3 mL). The mixture was transferred to as eparating funnel, the aqueous layer was extracted with Et 2 O( 3 10 mL), and the combined organic phases were washed with 1 m HCl (3 10 mL) and brine (3 10 mL), then filtered through water-repellent filter paper. Solvent was removed in vacuo and the crude product purified (when needed).
Phenyl[oxo(phenyl)(piperidin-1-yl)-l 6 N-Aminocarbonylation of sulfonimidamide 2aa(urea formation): General procedure E [52] To as olution of sulfonimidamide 2aa (100 mg, 0.45 mmol, 1.0 equiv) in anhydrous DCM (0.9 mL), the corresponding isocyanate (0.66 mmol, 1.5 equiv) was added dropwise at RT under Ar atmosphere. The reaction mixture was stirred until ap recipitate formed (3-16 h) and starting material had been consumed (TLC analysis). Et 2 Ow as added, and the precipitate was collected by filtration under reduced pressure and washed with Et 2 O. The solid was purified by flash column chromatography (when needed).
1-[Oxo(phenyl)(piperidin-1-yl)-l 6 -sulfanylidene]-3-propylurea (2 ga) Prepared according to general procedure E, from n-propyl isocyanate;c rude purified by flash column chromatography (KP-Sil, 0-100 %E tOAc in PE) to give 2ga as ac olorless oil (89 mg, 65 %): 
